Opportunities emerging in a world reshaped by COVID-19; top trends in functional foods and beverages; pet nutrition trends; contract manufacturing; delivering quality dietary supplements and much more, these staff-written articles got the most clicks throughout 2021 at NutraceuticalsWorld.com.
 
 
Post COVID-19: A New World of Health & Nutrition Opportunities
The pandemic has reshuffled consumer health priorities, and reshaped wellness markets for the foreseeable future.
 

Key Trends in Functional Foods & Beverages for 2021
If you want to succeed in the business of food and health, reinventing traditional foods will give you the greatest chance of success, as it has done for years.
 

Probiotics & Prebiotics: The EU Ban is Shaking
Some countries have not accepted the European Commission’s limitations on the term ‘probiotic’ and have implemented their own interpretations.
 

Pet Nutrition: In the From-Home Era, Consumers Tune into Health Needs of Four-Legged Friends
With trends in pet supplements corresponding with popular human health concerns, the outlook for specialty products is promising.

 
Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.

 
Delivering Dietary Supplements that Exceed Consumer Expectations
Sophisticated and innovative dosage formats can help position brands for success.

 
Could Terpenes Be The Next Big Thing in Supplements?
Although volatile and hard to manage, terpenes offer botanic properties popular with today’s consumers without the regulatory hassles of CBD.

 
Following the Ascent of Alternative Proteins
As the protein palate of global consumers turns greener, concerted efforts to create nutritionally optimized, appealing options abound.

 
Sustaining Plant-Based Momentum: A Cautionary Tale
Nearly half of adults look for products labeled ‘plant-based.’ Market opportunities abound.

 
FDA Rejects Two New Dietary Ingredient Notifications for CBD
The decision likely means the agency will not approve future NDIs for CBD barring a directive from Congress.